創薬における人工知能市場：提供、技術、プロセス、用途、治療領域、エンドユーザー別-2024-2030年の世界予測

創薬における人工知能市場規模は2023年に10億8,000万米ドルと推計され、2024年には13億5,000万米ドルに達し、CAGR 27.10％で2030年には58億1,000万米ドルに達すると予測されます。

創薬における人工知能は、新薬化合物の発見、設計、最適化のプロセスにおける機械学習アルゴリズムとAIシステムの応用を指します。これらのAIモデルは、従来複雑で時間のかかる創薬プロセスを合理化する上で極めて重要な役割を果たし、医療分野の進歩を促進します。市場の成長を後押ししているのは、世界の慢性疾患の負担増と、創薬の精度、スピード、有効性を高めるためにバイオ医薬品企業全体でAIの採用が増加していることです。さらに、前臨床試験中に生成される膨大なデータを管理する必要性が高まっていることも、市場の成長を後押ししています。ヘルスケアにおけるより熟練したAI専門家の必要性と、AI導入に伴う高コストが成長の限界に影響を与えています。データセットの利用可能性が限られていることは、創薬におけるAIの成長を抑制する極めて重要な課題です。新規創薬メカニズムや個別化医療に関連する分野にはビジネスチャンスがあります。医薬品開発のためのAI研究の急成長分野における技術進歩は、創薬、疾患理解、患者特異的治療の強化の可能性を生み出します。

提供AIソフトウェアが創薬への革命的アプローチを提案

創薬の分野では、人工知能（AI）がプロセスを迅速化し、精度を高め、最終的に成果を向上させる幅広いサービスを提供しています。これらのサービスには主に、構造解析、薬剤の再配置、薬力学モデリングなどが含まれます。AIソフトウェアは、創薬におけるデジタル革命を促進しました。AIを創薬に取り入れた結果、さまざまなソフトウェア・ソリューションが登場しました。これらのソフトウェアには、予測分析、分子ドッキング、精密医療、患者と最も効果的な薬剤のマッチングを加速させるモデリング・分析ソフトウェアなどが含まれます。

技術：個別化治療におけるコンテキスト認識処理の採用拡大

AIアルゴリズムが遺伝子データ、バイオマーカー、疾患指標を相互参照し、潜在的な創薬ターゲットやオーダーメイド治療法を提案します。機械学習もAIの一分野であり、化合物の特性や患者の反応を予測し、薬剤設計を強化することで、プログラムされていないインテリジェントな意思決定を促進します。一方、自然言語処理は、データマイニングのために人間の言語の力を利用し、学術的なソースからの情報を同化してデータの包括性を強化します。文脈を考慮した処理は、個人に合わせた治療法の提案を行い、機械学習は薬剤設計の最適化を推進します。逆に、自然言語処理は大規模なデータセットを活用し、新薬と疾患の関連を特定します。これらのテクノロジーは、単独で機能するのではなく、収束する可能性があり、正確で迅速な創薬が期待できます。

プロセス計算能力と予測能力による創薬プロセスの大幅な強化

創薬における人工知能（AI）の世界では、候補化合物の選択と検証は、有望な創薬候補化合物の潜在的な成功をしっかりと評価する上で極めて重要なステップです。AIアルゴリズムは分子構造を分析し、その効果を予測し、実行可能性を判断します。次のステップでは、ヒットの特定と優先順位付けが行われ、AIスクリーニングから得られた有望な医薬品候補のリストが準備されます。これらのヒットは、効力、選択性、安全性に基づいて優先順位付けされます。ヒットの同定に続いて、ヒットからリードへの同定またはリードの生成段階では、「ヒット」を「リード」、すなわちさらに最適化できる潜在的な医薬品候補に変えることに焦点を当てる。ここでAIは、医薬品化学者が化合物を試験し最適化することで、リードの評価と最適化を支援します。次の段階はリードの最適化で、潜在的な医薬品候補が活性、特異性、安全性を向上させるために強化されます。この段階では、潜在的な副作用を予測する高度なAI技術と、薬効を高めるための手法が必要となります。創薬プロセスにはターゲットの同定と選択も含まれ、これは薬剤の疾患修飾ターゲットの選択に関与します。最終段階はターゲットの検証で、選択されたターゲットが疾患の進行に果たす役割と、薬剤によって調節される可能性を検証します。人工知能は、計算能力と予測能力によって各ステップを強化することで、創薬に革命を起こし続けています。人工知能は創薬の効率を大幅に高め、命を救う薬をより早く市場に送り出す可能性を高めています。

応用AIが設計した低分子医薬品のヒト臨床試験への利用が拡大しています。

生物製剤の分子標的薬は、より迅速で正確な最適化のためにAIを活用しており、AlphaFoldはかなりのタンパク質予測能力を実証し、創薬を迅速化しています。AIアルゴリズムは、より正確にパターンを解読することで疾患の特定と評価を強化し、早期介入を可能にします。医薬品開発における安全性、毒性、コンプライアンスチェックは、AIを活用して毒性を予見し、安全性を高めてコストを削減します。COVID-19の中で、効率的なワクチン設計と最適化は非常に重要であり、AIを活用したウイルス病原領域の特定によって促進されます。このように、AIは医薬品の革新にとって極めて重要であり、疾患の特定、治療薬の設計、安全性遵守の確保に役立っています。

治療領域：個別化されたがん治療のための創薬におけるAIの採用増加。

人工知能（AI）は、早期発見から個別化された投薬製造に至るまで、心血管疾患管理における変革ツールとして台頭してきています。AIアプリケーションは免疫腫瘍学での利用が増加しており、治療反応の分類と予測に役立っています。企業や調査は、糖尿病から肥満まで、代謝性疾患の理解と治療に革命を起こすためにAIを利用しています。神経変性疾患の診断と治療法の開発に役立つAIの可能性は、この分野全体で認識されています。

エンドユーザー：製薬会社やバイオテクノロジー企業による創薬プロセス加速のためのAI活用の増加

医薬品開発業務受託機関（CRO）はAIを活用して創薬サービスを大幅に強化し、高品質で効率的な成果を提供しています。AIを活用した創薬に取り組むCROは一般的に、ワークフローを合理化し、創薬スピードを加速し、人的ミスを最小限に抑えるように設計されたソリューションを好みます。創薬の牽引役である製薬会社やバイオテクノロジー企業は、AIにかなりの親和性を示しています。AIは、創薬プロセスを迅速化し、薬剤反応を予測し、薬剤の失敗に関連するコストを削減することで、これらの業界を支援しています。

研究センターや学術・政府機関は、創薬におけるAIの可能性をますます活用するようになっています。ここでの嗜好は、潜在的な薬剤候補を予測し、試行錯誤の事例を最小限に抑え、正確な研究のために膨大なデータを吸収するAIの力にあります。AIの活用度合いはエンドユーザーによって異なるが、そのポジティブな影響は疑いようがないです。その精度、スピード、費用対効果を通じて創薬に革命をもたらすAIの可能性は、この分野全体でますます認識されるようになっています。

地域別の洞察

米国は、活発なスタートアップ環境と政府からの強力な資金提供により、AIを創薬に統合する最前線に立っています。カナダは、AI主導の創薬プラットフォームに多額の投資を行っており、この献身的な姿勢に共鳴しています。英国、フランス、ドイツなどの欧州諸国は、AIとデータサイエンスを活用して創薬手順に革命をもたらしつつあり、その背景には学術機関と製薬業界の戦略的協力関係があります。中国、日本、インドを筆頭に、アジア太平洋は説得力のあるダイナミクスを提供しています。中国の大規模なAI投資は、日本の卓越した製薬研究と相まって、創薬におけるAIの採用を促進しています。インドでは、政府の支援と拡大するIT部門が創薬のAI化を進めています。米国、中国、EUはAI創薬に関する特許請求でリードしており、それぞれの製薬業界における一貫したイノベーションを象徴しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、創薬における人工知能市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、創薬における人工知能市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.創薬における人工知能市場の市場規模および予測は？

2.創薬における人工知能市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.創薬における人工知能市場の技術動向と規制枠組みは？

4.創薬における人工知能市場における主要ベンダーの市場シェアは？

5.創薬における人工知能市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 創薬プロセスの制御とコスト削減の需要
    • 前臨床研究中に生成される大量のデータを管理する必要性が高まる
    • バイオ医薬品企業での導入拡大
  • 抑制要因
    • 熟練した専門家の不足
  • 機会
    • AIクラウドが創薬における合理化と自動化のアプローチを実現
    • 増加する研究開発投資
  • 課題
    • データセットの入手が制限される
• 市場セグメンテーション分析
  • 提供内容：AIソフトウェアが創薬への革新的なアプローチを提案
  • テクノロジー：パーソナライズされた治療におけるコンテキスト認識処理の採用拡大
  • プロセス：計算能力と予測能力による創薬プロセスの大幅な強化
  • 応用：ヒト臨床試験におけるAI設計の低分子医薬品の使用が増加しています。
  • 治療領域：個別化がん治療のための創薬におけるAIの採用の増加。
  • エンドユーザー：製薬企業やバイオテクノロジー企業による創薬プロセスの加速化を目的とした創薬におけるAIの利用増加
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 創薬における人工知能市場：提供別

• サービス
• ソフトウェア

第7章 創薬における人工知能市場：技術別

• コンテキスト認識処理
• 機械学習
• 自然言語処理

第8章 創薬における人工知能市場：プロセス別

• 候補者の選定と検証
• ヒットの識別と優先順位付け
• ヒット・トゥ・リードの特定/リード生成
• リード最適化
• ターゲットの特定と選択
• ターゲット検証

第9章 創薬における人工知能市場：用途別

• 生物製剤の設計と最適化
• 病気の特定と評価
• 安全性、毒性、コンプライアンス評価
• 低分子設計と最適化
• ワクチンの設計と最適化

第10章 創薬における人工知能市場治療領域別

• 循環器疾患
• 免疫腫瘍学
• 代謝性疾患
• 神経変性疾患

第11章 創薬における人工知能市場：エンドユーザー別

• 契約調査機関
• 製薬・バイオテクノロジー企業
• 研究センターおよび学術・政府機関

第12章 南北アメリカの創薬における人工知能市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の創薬における人工知能市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの創薬における人工知能市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • メルク、AIを活用した創薬を強化するため2つの戦略的提携を締結
  • インシリコのフェーズ IIプログラムの開始は、ジェネレーティブ AIの勢いを浮き彫りにする
  • Google Cloud、AIを活用した創薬と精密医療を安全に加速するソリューションを発表
• 戦略分析と提言

第16章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET RESEARCH PROCESS
• FIGURE 2. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET DYNAMICS
• FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 22. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 27. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 28. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTEXT-AWARE PROCESSING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTEXT-AWARE PROCESSING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CANDIDATE SELECTION & VALIDATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CANDIDATE SELECTION & VALIDATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT-TO-LEAD IDENTIFICATION/ LEAD GENERATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY HIT-TO-LEAD IDENTIFICATION/ LEAD GENERATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & SELECTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION & SELECTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS DESIGN & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS DESIGN & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISEASE IDENTIFICATION & ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY DISEASE IDENTIFICATION & ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SAFETY, TOXICITY, & COMPLIANCE ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SAFETY, TOXICITY, & COMPLIANCE ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DESIGN & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DESIGN & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY VACCINE DESIGN & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY VACCINE DESIGN & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY IMMUNO-ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY IMMUNO-ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 103. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 104. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 105. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 106. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 107. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 108. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 109. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 112. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 113. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 114. CANADA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 167. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 168. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 169. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 170. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 171. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 172. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 173. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 176. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 177. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 178. CHINA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 179. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 180. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 181. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 182. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 183. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 184. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 185. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 188. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 189. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 190. INDIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SIZE, BY PROCESS, 2018-20

[196 Pages Report] The Artificial Intelligence in Drug Discovery Market size was estimated at USD 1.08 billion in 2023 and expected to reach USD 1.35 billion in 2024, at a CAGR 27.10% to reach USD 5.81 billion by 2030.

Artificial Intelligence in drug discovery refers to the application of machine learning algorithms and AI systems in the process of discovering, designing, and optimizing new drug compounds. These AI models play a pivotal role in streamlining the traditionally complex and time-consuming drug discovery process, thus facilitating advancements in the field of medicine. The market growth is propelled by the growing burden of chronic diseases worldwide and the rising adoption of AI across biopharmaceutical companies for heightened precision, speed, and effectiveness in drug discovery. Moreover, the increasing need to manage the large data generated during preclinical studies drives market growth. The need for more skilled AI professionals in healthcare and the high costs associated with implementing AI is influencing growth limitation. The limited availability of data sets is a pivotal challenge curtailing the growth of AI in drug discovery. The opportunities are poised in fields related to novel drug discovery mechanisms and personalized medicine. Technological advancement in the burgeoning areas of AI research for drug development creates a potentiality for enhanced drug discovery, disease understanding, and patient-specific treatments.

Offering: AI Software propose a revolutionary approach to drug discovery

Within the field of drug discovery, Artificial Intelligence (AI) offers a robust range of services that expedite the process, enhance accuracy, and ultimately improve outcomes. These services majorly include structural analysis, drug repositioning, and pharmacodynamics modeling. AI software has catalyzed a digital revolution in drug discovery. Distinct software solutions have surfaced as a product of integrating AI into drug discovery. These software include predictive analytics, molecular docking, precision medicine, and modeling and analysis software to speed up matching a patient to the most effective.

Technology: Growing adoption of context-aware processing in personalized therapeutic

Context-aware processing is personalized, with AI algorithms cross-referencing genetic data, biomarkers, and disease indicators to suggest potential drug targets or bespoke treatments. Machine learning, another AI subfield, facilitates intelligent, unprogrammed decisions, predicting compound traits, patient reactions, and enhancing drug design. Natural language processing, meanwhile, harnesses the power of human language for data mining, assimilating information from academic sources to fortify data inclusivity. Context-aware processing offers personalized therapeutic recommendations, whereas machine learning drives the optimization of drug design. Conversely, natural language processing leverages large datasets to identify novel drug-disease associations. Rather than working in isolation, these technologies have convergent potentials, promising precise, expedited drug discovery.

Process: Significant augmentation in the drug discovery process with computational prowess and predictive capabilities

In the Artificial Intelligence (AI) world in drug discovery, candidate selection and validation is a crucial step in robustly assessing the potential success of prospective drug candidates. AI algorithms analyze molecular structures, predict their effect, and determine their viability. The next step involves hit identification and prioritization, prepping a list of promising drug candidates derived from AI screening. These hits are prioritized based on potency, selectivity, and safety. Following hit identification, the hit-to-lead identification or lead generation stage focuses on transforming the 'hits' into 'leads,' i.e., potential drug candidates that can be further optimized. Here, AI helps to evaluate and optimize leads with medicinal chemists testing and optimizing compounds. The next segment represents lead optimization, where potential drug candidates are enhanced for improved activity, specificity, and safety. This stage necessitates advanced AI technology to predict potential side effects and methodology to enhance drug efficacy. The drug discovery process also encompasses target identification and selection, which involves the choice of disease-modifying targets for the drug. The final stage is target validation, which verifies the selected target's role in the progression of the disease and its potential to be modulated by a drug. Artificial Intelligence continues revolutionizing drug discovery by augmenting each step with computational power and predictive capabilities. It significantly enhances drug discovery's efficiency and potential to deliver life-saving drugs to the market faster.

Application: Growing usage of AI-designed small molecule drugs for human clinical trials.

Biologics molecular-targeted drugs leverage AI for speedier and more accurate optimization, with AlphaFold demonstrating considerable protein prediction capabilities, expediting drug discovery. AI algorithms enhance disease identification and assessment by decoding patterns more accurately, allowing earlier interventions. Safety, toxicity, and compliance checks during drug development leverage AI to foresee toxicities, augmenting safety and decreasing costs/ Small molecule drug discovery, usually time-consuming, is being revolutionized by AI. Amidst COVID-19, efficient vaccine design and optimization are critical and facilitated by AI-enabled identification of viral pathogenic regions. Thus, AI is pivotal for pharmaceutical innovations, aiding in identifying diseases, designing therapeutics, and ensuring safety compliance.

Therapeutic Area: Rising adoption of AI in the drug discovery for personalized cancer treatment.

Artificial intelligence(AI) has been emerging as a transformative tool in cardiovascular disease management, ranging from early detection to personalized medication production. AI applications are seeing increased use in immuno-oncology, where they help classify and predict treatment responses. Companies and researchers are using AI to revolutionize the understanding and treatment of metabolic diseases, from diabetes to obesity. AI's potential to aid in diagnosing and developing treatments for neurodegenerative diseases has been recognized across the sector.

End User: Increasing use of AI in the drug discovery by pharmaceutical and biotechnology companies to accelerate their drug discovery process

Contract research organizations(CROs) leverage AI to significantly augment their drug discovery services, offering high-quality and efficient outcomes. CROs dealing with AI-powered drug discovery generally prefer solutions designed to streamline their workflow, accelerate the speed of discovery, and minimize human errors. Pharmaceutical and biotechnology companies, leading drug discovery drivers, show considerable affinity towards AI. AI facilitates these industries in expediting the drug discovery process, predicting drug response, and reducing costs associated with drug failure.

Research centers and academic & government institutes are increasingly capitalizing on AI's potential in drug discovery. The preference here lies in AI's power to predict potential drug candidates, minimize trial and error instances, and absorb vast data for precise research. Although the degree of AI utilization varies among end users, its positive impact is unmistakable. AI's potential to revolutionize drug discovery through its precision, speed, and cost-effectiveness is increasingly recognized across the field.

Regional Insights

The U.S. stands at the forefront of integrating AI into drug discoveries, fuelled by an active start-up environment and robust governmental funding. Canada echoes this dedication with considerable investment in AI-driven discovery platforms. European countries, such as the UK, France, and Germany, are leveraging AI and data science to revolutionize drug discovery procedures, attributed to strategic collaboration between academic institutions and the pharmaceutical industry. With China, Japan, and India at the helm, Asia-Pacific offers compelling dynamics. China's massive AI investment, paired with Japan's excellence in pharmaceutical research, is fostering the adoption of AI in drug discovery. In India, governmental support and an expanding IT sector are moving towards AI in drug discoveries. The U.S., China, and EU lead in patent claims for AI drug discoveries, representing consistent innovation in their pharmaceutical industries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Artificial Intelligence in Drug Discovery Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Artificial Intelligence in Drug Discovery Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Aria Pharmaceuticals, Inc., Atomwise, Inc., BenevolentAI Limited, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., Cyclica Inc., Deargen Inc., Deep Genomics Incorporated, Envisagenics, Inc., Euretos Services BV, Exscientia PLC, Insilico Medicine, Insitro, Inc., International Business Machines Corporation, InveniAI LLC, Microsoft Corporation, Novartis AG, NVIDIA Corporation, Oracle Corporation, Owkin, Inc., Verge Genomics Inc., and XtalPi Inc..

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Offering
  • Services
  • Software

• Technology
  • Context-Aware Processing
  • Machine Learning
  • Natural Language Processing

• Process
  • Candidate Selection & Validation
  • Hit Identification & Prioritization
  • Hit-to-lead Identification/ Lead generation
  • Lead Optimization
  • Target Identification & Selection
  • Target Validation

• Application
  • Biologics Design & Optimization
  • Disease Identification & Assessment
  • Safety, Toxicity, & Compliance Assessment
  • Small Molecule Design & Optimization
  • Vaccine Design & Optimization

• Therapeutic Area
  • Cardiovascular Disease
  • Immuno-Oncology
  • Metabolic Diseases
  • Neurodegenerative Diseases

• End User
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Research Centers and Academic & Government Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Artificial Intelligence in Drug Discovery Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Artificial Intelligence in Drug Discovery Market?

3. What are the technology trends and regulatory frameworks in the Artificial Intelligence in Drug Discovery Market?

4. What is the market share of the leading vendors in the Artificial Intelligence in Drug Discovery Market?

5. Which modes and strategic moves are suitable for entering the Artificial Intelligence in Drug Discovery Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Demand to Control Drug Discovery Process and Reduce Cost
    • 5.1.1.2. Increasing Need to Manage the Large Data Generated During Preclinical Studies
    • 5.1.1.3. Increasing Adoption across Biopharmaceutical Companies
  • 5.1.2. Restraints
    • 5.1.2.1. Unavailability of Skilled Professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. AI Cloud to Create a Streamlined and Automated Approach in Drug Discovery
    • 5.1.3.2. Increasingly Growing R&D Investments
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Availability of Data Sets
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: AI Software propose a revolutionary approach to drug discovery
  • 5.2.2. Technology: Growing adoption of context-aware processing in personalized therapeutic
  • 5.2.3. Process: Significant augmentation in the drug discovery process with computational prowess and predictive capabilities
  • 5.2.4. Application: Growing usage of AI-designed small molecule drugs for human clinical trials.
  • 5.2.5. Therapeutic Area: Rising adoption of AI in the drug discovery for personalized cancer treatment.
  • 5.2.6. End User: Increasing use of AI in the drug discovery by pharmaceutical and biotechnology companies to accelerate their drug discovery process
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Artificial Intelligence in Drug Discovery Market, by Offering

• 6.1. Introduction
• 6.2. Services
• 6.3. Software

7. Artificial Intelligence in Drug Discovery Market, by Technology

• 7.1. Introduction
• 7.2. Context-Aware Processing
• 7.3. Machine Learning
• 7.4. Natural Language Processing

8. Artificial Intelligence in Drug Discovery Market, by Process

• 8.1. Introduction
• 8.2. Candidate Selection & Validation
• 8.3. Hit Identification & Prioritization
• 8.4. Hit-to-lead Identification/ Lead generation
• 8.5. Lead Optimization
• 8.6. Target Identification & Selection
• 8.7. Target Validation

9. Artificial Intelligence in Drug Discovery Market, by Application

• 9.1. Introduction
• 9.2. Biologics Design & Optimization
• 9.3. Disease Identification & Assessment
• 9.4. Safety, Toxicity, & Compliance Assessment
• 9.5. Small Molecule Design & Optimization
• 9.6. Vaccine Design & Optimization

10. Artificial Intelligence in Drug Discovery Market, by Therapeutic Area

• 10.1. Introduction
• 10.2. Cardiovascular Disease
• 10.3. Immuno-Oncology
• 10.4. Metabolic Diseases
• 10.5. Neurodegenerative Diseases

11. Artificial Intelligence in Drug Discovery Market, by End User

• 11.1. Introduction
• 11.2. Contract Research Organizations
• 11.3. Pharmaceutical & Biotechnology Companies
• 11.4. Research Centers and Academic & Government Institutes

12. Americas Artificial Intelligence in Drug Discovery Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Artificial Intelligence in Drug Discovery Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Artificial Intelligence in Drug Discovery Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
  • 15.3.2. Launch of Insilico's Phase II Program Highlights Generative AI Momentum
  • 15.3.3. Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
• 15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

• 16.1. Key Company Profiles
• 16.2. Key Product Portfolio